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SHORT COMMUNICATION
Effect of interleukin 2 on urinary excretion of degradation products of
prostacyclin and thromboxane A, in patients with ovarian cancer
A Aitokallio-Tallberg, P Lehtovirta, J Vartiainen and 0 Ylikorkala
Departments ofObstetrics and Gynaecology, University ofHelsinki, Haartmaninkatu 2, SF-00290 Helsinki, Finland.
Summary We studied the effect of intraperitoneal recombinant interleukin 2 (rIL-2) on the production of
prostacyclin (PGI2) and thromboxane A2 (TxA2) in six patients with metastatic ovarian malignancy. Time-span
urine samples collected before and after 17 intraperitoneal instillations of IL-2 (6 x 105 IU m-2) were assessed
for 2,3-dinor-6-keto-prostaglandin Flj (dinor-6-keto; a metabolite reflecting the in vivo product of PGI2) and
2,3-dinor-thromboxane B2 (dinor-TxB2; a metabolite reflecting the production of TxA2). Analysis was by
high-pressure liquid chromatography, followed by radioimmunoassay. Recombinant IL-2 administration was
accompanied by a significant rise (85%; P<0.02) in the output of dinor-6-keto within the first 2h, and this
elevation persisted for up to 6 h. Moreover, output of dinor-TxB2 also rose; this rise (30%) was significant
(P<0.02) 6 h after the instillation. These effects may, in some yet unknown manner, prove significant in the
anti-cancer action of rIL-2.
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One way the human body resists cancer cells is through
activated T lymphocytes which secrete a large number of
cytokines (Borden and Sondel, 1990). One of these mediat-
ors, interleukin 2 (IL-2) (Boyer et al., 1989; Borden and
Sondel, 1990), can nowadays be produced in large quantities
through recombinant DNA technology. Synthetic recom-
binant IL-2 (rIL-2) is considered to show promise as an
adjuvant therapy for patients with primary or recurrent
cancer (Beller et al., 1989; Boyer et al., 1989; Thomas and
Sikora, 1991; Budd et al., 1992). rIL-2, when administered
intravenously however (Oliver et al., 1989; Budd et al., 1992),
shows a high rate of severe systemic toxic side-effects (such as
pulmonary oedema), a fact which limits the use of this
approach. By giving rIL-2 intraperitoneally (i.p.), we can
reduce systemic side-effects and perhaps achieve a better
therapeutic response in patients with metastatic gynae-
cological malignancies; results are, thus far, controversial
(Beller et al., 1989; Bertoglio et al., 1989; Thomas and
Sikora, 1991; Lissoni et al., 1992).
The mechanism(s) by which rIL-2 operates in patients with
ovarian cancer are unknown, but in view of the high produc-
tion in ovarian cancer of vasoactive prostanoids such as
prostacyclin (PGI2) and thromboxane A2 (TxA2) (Aitokallio-
Tallberg et al., 1988), an effect of rIL-2 on PGI2 and TxA2
could be possible. We therefore studied the effect of i.p.
administration of rIL-2 on production of PGI2 and TxA2 in
patients with metastatic ovarian cancer.
Patients and methods
The study involved six patients with residual epithelial
ovarian cancer (0.5-2 cm in pelvic serosae) documented his-
tologically at the second-look operation (five serous adeno-
carcinomas stage III, and one mesonephroid carcinoma stage
II according to the primary staging). All had undergone
surgery for their primary carcinoma, plus treatment with 6-8
monthly cycles of chemotherapy (cisplatin 60mgm2 and
cyclophosphamide 1000mg m-2). An indwelling catheter
(Port-A-Cath) for delivery of IL-2 was inserted during the
second-look operation, and 3-5 weeks later the first bolus
(6 x 105 IUm2) of rIL-2 (Euro Cetus, Amsterdam, The
Netherlands) was given in 250 ml physiological Ringer-lactate
through the catheter. The rIL-2 courses were to be repeated
16 times at one week intervals, but our study focused on the
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first instillation with the exception of one patient who was
serially followed (see below). This study was approved by the
local ethics committee.
All six patients collected urine samples (see below) at the
time of the first rIL-2 injection, and one patient provided
urine samples during an additional 11 courses of rIL-2. The
urine samples were collected as follows: the first collection
during the 3 h before the treatment, the second during the
2 h from the start of the instillation of the rIL-2 and the
third from hours 2-6 after the instillation, and the fourth 3 h
sample 1 week after the treatment.
Urines were kept frozen at - 25°C until assayed for 2,3-
dinor-6-keto-PGFI. (dinor-6-keto) and 2,3-dinor-TxB2 (dinor-
TxB2) by use of high-pressure liquid chromatography
(HPLC), followed by radioimmunoassay; the details of the
methods have been described elsewhere (Tulppala et al.,
1991).
Prostanoid excretions, given as medians and ranges, are in
pgmin'1.
The significance of the difference was analysed by Stud-
ent's t-test for paired data.
Results
No significant changes in platelet or white-cell count,
haemoglobin, liver enzymes or any other laboratory tests
appeared following the rIL-2 injection (data not shown). In
peritoneal lavage 1 week after the first injection, no malig-
nant cells could be found in any patient. One patient
reported transient arthalgia and another one slight itching
the day after the injection; no other side-effects were seen.
The baseline output of dinor-6-keto ranged from 22 to
141 pgmin-' (median 47pgmin '). It rose by 85% (P<
0.02) within the first 2 h of the injection of rIL-2 (median
87.0 pgmin-', range 33-298), and remained elevated for the
next 4 h (median 87 pgmin ', range 15-209). For the one
patient studied during an additional 11 courses of rIL-2,
dinor-6-keto output returned to the baseline output 1 week
after each injection (median 47.0pgmin-', range 28-110)
(Figure 1).
Dinor-TxB2 output rose (25%) from a median of 143
pgmin-' (range 51-250) to 179 pgmin-' (range 100-355) in
2 h after the injection. The rise continued for the next 4 h
(median of 186 pg min-', range 64-456, P<0.02). The
dinor-TxB2 excretion had returned to the baseline level
(median 141.0, range 52-197) within 1 week after treatment
(Figure 2).Effect of IL-2 on prostacyclin and thromboxaneexcretion
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Figure 1 Urinary excretion (pg min- ; median) of dinor-6-keto-
PGFI, in ovarian cancer patients before the intraperitoneal instill-
ation of rIL-2, during the first 2 h of instillation, during hours
2-6 after instillation and I week after the treatment.
The ratio of dinor-6-keto output to dinor-TxB2 output did
not change significantly during the treatment (P>0.07).
Discussion
The intraperitoneal instillation of rIL-2 for patients with
metastatic gynaecological cancer has limited cancer growth
according to many studies (Rosenberg et al., 1987; Budd et
al., 1992; Lissoni et al., 1992) although not in all (Beller et
al., 1989; Steis et al., 1990). We explored whether such a
treatment affects the production of PGI2 and TxA2, which
are excessively produced by ovarian cancer (Aitokallio-
Tallberg et al., 1988) and which are certainly involved in
tumour and immunological processes (Xiao and Levine,
1986; Gibbons et al., 1987; Janniger and Racis, 1987; Ruiz et
al., 1988, 1992; Moore et al., 1989).
It is clear from our data that i.p. administration of rIL-2
led to a significant increase in PGI2 synthesis, as assessed by
urinary 2,3-dinor-6-keto-PGFIe., output, which is regarded as
the most representative method to assess PGI2 production in
vivo (FitzGerald et al., 1983, 1987; Ylikorkala et al., 1986;
Oates et al., 1988). Our findings are in general agreement
with data on the increased levels of 6-keto-PGFI., in plasma
in sheep which were infused intravenously with rIL-2 (O'Neill
et al., 1991), although the value of plasma 6-keto-PGFIc,
measurement as an index of PGI2 can be questioned. Our
data do not allow us to deduce the origin of the PGI2
increase, but most probably it came from the endothelial
cells, with which rIL-2 may interfere, or from stimulated T
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Figure 2 Urinary excretion (pg min-'; median) of dinor-TxB2 in
ovarian cancer patients before the intraperitoneal instillation of
rIL-2, during the first 2 h of instillation, during hours 2-6 after
instillation and I week after the treatment.
consider the cancer tissue as a possible source, especially as it
is known to produce PGI2 (Aitokallio-Tallberg et al., 1988),
but in view of the small size of the residual tumour and the
huge rise in PGI2 this explanation is not likely. The
significance of rIL-2-induced stimulation in PGI2 synthesis in
tumour behaviour or prognosis remains open in our study
with its rather small number of patients, but in theory, such
stimulation could prove beneficial (Honn et al., 1981, 1983).
rIL-2 is known to stimulate TxA2 production in different
animal models (Ferro et al., 1989; Klausner et al., 1989;
O'Neill et al., 1991; Rabinovici et al., 1992; Ruiz et al., 1992).
We have provided the first human data indicating that i.p.
administration of rIL-2 stimulates TxA2 synthesis, as seen
from a significant rise in the urinary output of 2,3-dinor-
TxB2, a reliable index for systemic TxA2 synthesis (Fitz-
Gerald et al., 1983, 1987; Ylikorkala et al., 1986; Oates et al.,
1988). As in the case of PGI2, we do not know the source of
TxA2 stimulation in these patients, but immune cells
(Schoultze et al., 1984; Remick et al., 1987), cancer tissue
(Aitokallio-Tallberg et al., 1988) or stimulated platelets are
probable candidates. The significance of rIL-2-induced TxA2
stimulation remains open in our study.
In summary, the i.p. administration of rIL-2 leads to pro-
found rises in PGI2 and TxA2 synthesis in patients with
metastatic ovarian cancer, rises which may be of significance
in the therapeutic response to rIL-2 administration.
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